Protection
- Encapsulation shields iron from oxidation and acid degradation.
- Improved GI tolerance at clinically effective doses.
Ferrous Ascorbate encapsulated in cationic PQNS nano-vesicles for direct intestinal uptake, superior cellular retention, and gut-friendly delivery.
Why Q-ERYTHRA™
Mechanism
Transporters & Pathways: DMT1 • Ferroportin • TRPML1 • Zip14; vesicles protect iron and target epithelial cells with higher retention.
Source: Q-ERYTHRA PDF — transporter list, oxidation protection, 3.6× retention.
Cellular Uptake (In-Vitro)
PQNS nanostructure improves solubility, stability, and trans-epithelial transport—explaining the higher cellular iron levels observed.
Clinical (25 Days)
Source: Q-ERYTHRA PDF — study design, endpoints, and results.
Formula
| Component | Role |
|---|---|
| PQNS Ferrous Ascorbate | Bioavailable iron for hemoglobin synthesis |
| Vitamin C, B12, Folic Acid | Iron reduction/transport • RBC maturation |
| Zinc • Copper • Cobalt (nano) | Heme formation & erythropoiesis cofactors |
| Phytochemicals | Support hepcidin balance & hematopoiesis |
Source: Q-ERYTHRA PDF — actives & cofactors list.
Comparison
| Attribute | PQNS Ferrous Ascorbate | Regular Ferrous Ascorbate |
|---|---|---|
| Bioavailability | High — Encapsulated & Protected | Moderate — Unstable in acid |
| GI Side Effects | Minimal | Frequent irritation |
| Release Profile | Controlled | Rapid/uneven |
| Hb Response | Faster improvement | Slower response |
| Cellular Retention | ≈3.6× higher | Limited |
FAQ
Is Vitamin C still needed? Included for reduction/transport; PQNS further stabilizes & delivers iron intracellularly.
Why cofactors (Zn/Cu/Co)? They’re catalytic for heme synthesis and erythrocyte maturation.
Tolerability? Encapsulation reduces unbound iron in the lumen, improving GI comfort.
Request the white paper, in-vitro appendix (ICP-MS), COAs, and the 25-day clinical summary.